Juno Therapeutics
JT
Active
· 2013Biotechnology company focused on developing cancer immunotherapies.
Juno Therapeutics
Biotechnology company focused on developing cancer immunotherapies.
About
Juno Therapeutics was a biopharmaceutical company founded in 2013, focused on developing a pipeline of cancer immunotherapy drugs, particularly CAR-T and TCR therapies. It was acquired by Celgene in 2018 for $9 billion.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
76Traction
40Team
70Visibility
2Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Juno Therapeutics do?
Juno Therapeutics was a biopharmaceutical company founded in 2013, focused on developing a pipeline of cancer immunotherapy drugs, particularly CAR-T and TCR therapies. It was acquired by Celgene in 2018 for $9 billion.
How much funding has Juno Therapeutics raised?
Juno Therapeutics has raised a total of $317M in funding. The most recent round on record is Series B.
Where is Juno Therapeutics headquartered?
Juno Therapeutics is headquartered in Seattle, United States.
When was Juno Therapeutics founded?
Juno Therapeutics was founded in 2013.
What industry does Juno Therapeutics operate in?
Juno Therapeutics operates in Biotechnology, Pharmaceuticals, Cancer Immunotherapy, Cart, TCR.
What is Juno Therapeutics's current status?
Juno Therapeutics's current operating status is: Acquired.